Healthlinx Limited (ASX:HTX) has been granted a US patent for its AGR2 Biomarker which forms part of the diagnostics for human tumours including ovarian and prostate cancers.
The patent is owned by the University of Liverpool in the United Kingdom which has been exclusively licensed to Healthlinx in 2007.
The patent has already been granted approval in Europe and Australia.
Healthlink says the patents further strengthen its position to further develop the biomarker.
Healthlinx booked a net loss of $826,000 in the first half of the 2012 financial year.
HTX Price at posting:
0.2¢ Sentiment: None Disclosure: Held
